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Abstract
Introduction: Among allergic rhinitis (AR) symptoms, nasal 
obstruction particularly affects the quality of life. Antihista-
mines and intranasal corticosteroids are the most frequently 
prescribed symptomatic drugs, but their efficacy is often in-
complete. Essential oils (EO) have shown an anti-inflamma-
tory effect and potential in treating patients with AR. The aim 
of this study was to evaluate the effectiveness of a hyper-
tonic EO-based nasal spray on perennial AR (PAR) symptoms. 
Methods: This prospective, open-label, non-randomized, 
multicentric trial included 43 patients with PAR sensitized to 
mites, not controlled for more than a year. All were treated 
with Puressentiel® Respiratory-Decongestant Nasal Spray 
for 30 days. Their usual treatment remained unchanged dur-
ing the study period. Before and after treatment, each par-
ticipant filled out a rhinitis questionnaire, the Allergic Rhini-
tis Control Test (ARCT). A nasal inspiratory peak flow (NIPF) 
was performed. Results: The mean ARCT was 16.4 and 20.5 
at D0 and D30, respectively (p < 0.001); the mean increase 
between D0 and D30 was 4.1 (p < 0.001). The proportion of 
patients with controlled rhinitis after 30 days of treatment 
was 69.8 versus 14% before treatment (p < 0.001). The mean 
NIPF was 86.5 L/min and 105.1 L/min at D0 and D30, respec-
tively (p < 0.001); the mean increase between D0 and D30 
was 18.5 L/min. Conclusion: A hypertonic EO-based nasal 
spray could be a new and natural option in the management 
of PAR. It could also be used as an add-on therapy when na-
sal symptoms are not fully controlled.
© 2020 The Author(s)
Published by S. Karger AG, Basel
Introduction
Allergic rhinitis (AR) is one of the most common man-
ifestations of immunoglobulin E-mediated inflammation 
after exposure of the nasal mucosa to allergens. The clas-
sical symptoms of AR are nasal congestion, nasal itch, 
rhinorrhea, and sneezing [1]. AR is very common in 
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Western countries, affecting 20–30% of the population, 
and evidence suggests that the prevalence of the disorder 
is increasing [2].
AR impairs quality of life, sleep, and social activities 
[3]. It is a significant cause of reduced productivity at 
work and absence from school. Poor sleep quality may 
induce diurnal somnolence. The impact is correlated with 
the severity of symptoms [1].
The main challenges in AR relate to its treatment. 
Overall, the guidelines for treatment are based on the fre-
quency, duration, and severity of symptoms [4]; the treat-
ment goal being the relief of symptoms and a reduction 
of their impact on quality of life. Therapeutic options 
available to achieve this goal include avoidance measures, 
oral antihistamines, intranasal corticosteroids, antileu-
kotrienes, nasal vasoconstrictors, and allergen immuno-
therapy [1]. The guidelines (ARIA) recommend different 
pharmacological treatments, which can be increased step 
by step according to disease severity [4]. Antihistamines 
and intranasal corticosteroids are the most frequently 
prescribed drugs for relieving AR symptoms [5] and are 
recommended as the first-line therapy, either alone or in 
combination. However, the effects of antihistamines on 
symptoms, especially nasal congestion, are modest [6]. 
Studies and meta-analyses have shown that intranasal 
corticosteroids are superior to antihistamines and leukot-
riene receptor in controlling the symptoms, particularly 
nasal congestion, in patients with moderate-to-severe AR 
[7, 8]. However, to achieve maximum benefit and relief, 
nasal corticosteroids should be used continually for 3–4 
weeks, thus underlining the importance of patient adher-
ence [9]. Indeed, adherence is imperative in the manage-
ment of AR, and lack of adherence can be an obstacle to 
effective treatment. One reason for non-adherence is 
that, although intranasal corticosteroids are the most ef-
fective pharmacotherapy for AR, their overall efficacy is 
moderate [6, 10], and most patients are concerned about 
long-term steroid treatment. Another common reason is 
the bothersome side effects, including nasal dryness, 
burning, stinging, sneezing [9], and bleeding [11].
There has been a recent increase in interest in the gen-
eral population regarding complementary and alternative 
medicine, and several review articles have been published 
on their role in treating allergic disease, including AR 
[12–14]. Instead of rejecting them bluntly, nondrug inter-
ventions for which beliefs are strong and the current lev-
el of evidence of their interest or deleterious effects is low 
need to be considered. Aromatherapy, especially the di-
rect inhalation of aroma compounds of essential oil (EO) 
fragrance, has long been used for various inflammatory 
diseases [15]. Recently, EOs containing monoterpenes 
have shown an anti-inflammatory effect in a murine 
model of asthma [16], as well as potential in treating pa-
tients with AR [17].
However, despite the potential of EOs in the treatment 
of AR, there have been few clinical trials on human AR 
patients that directly measure the effects on symptoms. 
Additional studies are needed to fully evaluate the effec-
tiveness and potential long-term benefits of these com-
pounds. The aim of the present study was to evaluate the 
efficacy on symptoms, particularly nasal congestion, of a 




Forty-three patients (33 women and 10 men) were recruited 
during a follow-up visit to the outpatient allergy clinic of 3 aca-
demic hospitals: 2 located in France (18 and 12 patients) and 1 in 
Belgium (13 patients). All patients fulfilled the following inclusion 
criteria: (i) over 18 years of age, (ii) diagnosed with AR according 
to ARIA and presenting clinical symptoms, (iii) over 1-year his-
tory of PAR, and (iv) with positive skin test results (wheal ≥3 mm 
compared with control) for at least 1 perennial allergen. Exclusion 
criteria were as follows: patients (i) receiving allergen immuno-
therapy, (ii) having had aromatherapy experience in the past, (iii) 
having had upper respiratory infection within the 8 previous weeks 
before inclusion or with chronic rhinosinusitis, (iv) with a history 
of drug allergy, (v) who were pregnant or breastfeeding, and (vi) 
with a history of neurological or psychiatric diseases.
Ethics, Consent, and Permissions
The study was approved by a local French Ethics Committee 
(Registration No. ID-RCB: 2018-A00836-49) and registered on 
ClinicalTrials.gov (No. NCT03963076). All participants signed an 
informed consent document, including consent for publication.
Study Protocol
This was a multicentric, prospective open-label, non-random-
ized study. All patients used Puressentiel® Respiratory-Deconges-
tant Nasal Spray (PRDNS) (Puressentiel Laboratory, Brussels, Bel-
gium), which is a combination of hypertonic seawater and organ-
ic rosemary floral water with 4 EOs (ravintsara, geranium, 
eucalyptus radiata, and niaouli). All ingredients contained in the 
spray are natural and comply with the BBDEO quality charter 
(biochemically and botanically defined EOs). The spray contains 
no propellant gas.
The patients were asked to use PRDNS twice a day for 4 weeks 
(2 sprays in each nostril morning and evening, every day at 8 a.m. 
and 8 p.m.). Evaluation procedures (listed below) at baseline be-
fore PRDNS administration (D0) were conducted at 10 a.m. The 
procedures after 4 weeks of PRDNS administration (D30) were 
also conducted at 10 a.m. Participants were not allowed to take any 
anti-allergic treatment (systemic or topical) apart from their usual 
one, which they continued without modification throughout the 
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study (40 patients). The 3 patients who had no treatment before 
inclusion in the study were not allowed to take any medication.
A spray bottle of PRDNS (15 mL) containing 4 EOs was pro-
vided to each patient. After 4-week administration, the patient 
brought back the bottle, which was weighed to assess compliance. 
All data are available at the study sites.
Outcomes
Rhinitis Control and Symptoms
AR control was assessed using the Allergic Rhinitis Control 
Test (ARCT), a self-completed questionnaire [18] consisting of 5 
questions, scored from 1 to 5. These individual scores were then 
added up to obtain a score ranging from 5 (worst score) to 25 (best 
score). An ARCT ≥ 20 was regarded as controlled AR; a lower score 
indicated uncontrolled AR [12]. The ARCT score was considered 
the primary outcome. It was measured at baseline (D0) and 4 
weeks after PRDNS administration (D30). Each subject also filled 
out a daily diary and was asked 5 questions concerning perception 
of discomfort and side effects (nasal dryness, burning, stinging, 
sneezing, and bleeding).
Nasal Inspiratory Peak Flow
Nasal inspiratory peak flow (NIPF), which measures basal flow 
and gives a direct measure of nasal obstruction (NO), was consid-
ered the secondary outcome [19]. The technique consists of appli-
cation of a face mask over the nose and obtaining 3 satisfactory 
maximal inspirations with the mouth closed. The highest result of 
the 3 was taken as the NIPF [19]. Measurements of NIPF were per-
formed at baseline (D0) before PRDNS administration and 4 
weeks later (D30).
Statistical Analysis
Stata software (StataCorp LLC, College Station, TX, USA) ver-
sion 15 and R software version 3.3 (the R Foundation for Statistical 
Computing, Vienna, Austria) were used for data management and 
data analysis, respectively. Continuous variables were summarized 
with descriptive statistics (number, mean, SD, range, and median), 
and frequency counts and percentages within each category were 
provided for categorical data. Statistics were computed for patients 
with available (i.e., non-missing) data. No imputation was per-
formed. Comparison of patient characteristics before and after 
treatment was done using Student’s t test for data in the case of 
continuous variable and the McNemar test for categorical variable. 
Differences between groups were considered statistically signifi-
cant if p values were <0.05. No attempt was made to adjust for 
multiple comparisons.
Sample Size Determination
This study was designed to detect an absolute improvement of 
20% between D0 and D30 in the score of nasal symptoms, assum-
ing that all patients at baseline were not controlled. To detect such 
a difference with 90% power (α = 0.05, 2-tailed test), 60 patients 
are required, assuming no dropout during the study. Due to enroll-




All patients were between 22 and 60 years of age, mean 
36.7 years (SD: 11). They were classified as persistent mild 
(n = 6) or persistent moderate-to-severe PAR (n = 37), 
according to the ARIA guidelines [4]. All were symptom-
atic at inclusion, with persistent NO. Among the 43 pa-
tients, all had a positive prick reaction to house dust mites, 
8 to house dust mites alone, 8 to house dust mites and cat 
dander, 16 to house dust mites and a seasonal allergen 
(grass, tree, or weed pollens). Forty patients were treated 
on a regular basis with antihistamines, either alone (19 
patients) or in combination with intranasal steroids (21 
patients), and in addition, some occasionally used decon-
gestants (5 patients) or oral corticosteroids (2 patients). 
Three patients had no regular treatment but used decon-
gestants as needed. All patients were nonsmokers. Pa-
tients were included between March and June 2019. All 
43 patients completed the 30 days of treatment.
Allergic Rhinitis Control Test
ARCT was assessable in the 43 patients at D0 and D30. 
The mean ARCT (Table 1) was 16.4 (3.2; range: 10–22) 
and 20.5 (3.7) at D0 and D30, respectively (p < 0.001), and 
the mean increase between D0 and D30 was 4.1 (3.7), p < 
0.001 (Table  1). The proportion of patients with con-
trolled rhinitis after 30 days of treatment with intranasal 
PRDNS administration was 69.8 versus 14% before treat-
Table 1. Changes in Allergic Rhinitis Control Test and NIPF between baseline (D0) and after 30 days of treatment 
(D30)
Parameter N D0 D30 p value
Controlled rhinitis (score >19), n (%) 43 6 (14.0%) 31 (69.8%) <0.001a
ARCT, mean (SD) 43 16.4 (3.2) 20.5 (3.7) <0.001b
NIPF (L/min), mean (SD) 42 86.5 (37.3) 105.1 (32.7) <0.001b
ARCT, Allergic Rhinitis Control Test; NIPF, nasal inspiratory peak flow. a McNemar test. b Student’s t test for 
paired data.
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ment (p < 0.001, McNemar test for paired data). Six pa-
tients had controlled rhinitis at D0 and remained con-
trolled at D30. If we consider only the patients with un-
controlled rhinitis at D0 (n = 37), the increase in ARCT 
between D0 and D30 remains highly significant (p < 
0.001). Individual values before and after treatment are 
shown in Figure 1.
Nasal Inspiratory Peak Flow
NIPF was assessable in 42 patients at D0 and D30. The 
mean NIPF (Table 1) was 86.5 L/min (37.3; range: 30–
200) and 105.1 L/min (32.7) at D0 and D30, respectively 
(p < 0.001), and the mean increase between D0 and D30 
was 18.5 (31.0) L/min (Table 1). Individual values before 
and after treatment are shown in Figure 2.
Adverse Side Effects
No adverse events were declared.
Compliance
To assess compliance, the weight of the PRDNS bottles 
was measured prior to the first use and at the end of the 
study. The mean baseline weight was 109.4 g (DS: 0), and 
post-study weight 70.2 g (DS: 12.6). The average amount 
of PRDNS used was 39.2 g (20.8), with variations from 
11.1 to 133.9 g. These values showed that patients did not 
always respect the prescribed dose. A sub-analysis of the 
efficacy of the product based on different doses did not 
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Fig. 1. Individual and median (red trian-
gles) values of Allergic Rhinitis Control 
Test (ARCT) before (D0) and after 1 month 
of treatment (D30) with Puressentiel® Re-
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Discussion/Conclusion
The current study was designed to investigate the ef-
fects of a nasal spray (PRDNS) of EOs on the perception 
of PAR symptoms using a validated self-completion 
questionnaire (ARCT) and nasal patency using a direct 
and objective measure of NO (NIPF). A marked improve-
ment in these 2 outcomes was observed after 4 weeks of 
PRDNS exposure (Table 1; Figs. 1, 2).
Disease control is now being considered as a major 
goal in the management of patients with AR, as already 
mentioned in the ARIA guidelines [4]. In this report, we 
used the ARCT, a reproducible, quick, and easy test to 
perform [18]. The latter is a 5-item self-assessment ques-
tionnaire [18], which had been validated by testing in 902 
patients before treatment and 2 weeks after treatment. 
The score at inclusion correlated significantly with the 
patient’s overall clinical status and the impact of AR on 


































Fig. 2. Individual and median (red trian-
gles) values of nasal inspiratory peak flow 
(NIPF) before (D0) and after 1 month of 
treatment (D30) with Puressentiel® Respi-
ratory-Decongestant Nasal Spray 
(PRDNS).
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was observed after 2 weeks of treatment [18]. A score of 
20 was found to be the optimal cutoff for poor versus well-
controlled rhinitis [18]. In our study, a significant in-
crease in ARCT score was noted (Table 1; Fig. 1), 70% of 
the patients reported good control (ARCT ≥ 20) at D30 
versus 14% before PRDNS administration. The mean im-
provement of ARCT was 4.1, which is above the mini-
mum clinical important difference (data not shown). This 
indicates that the administration of PRDNS had benefi-
cial effects on some aspect of their rhinitis that bothered 
them, such as sleep, daily activities/sports, work, and 
troublesome symptoms.
Among the symptoms of AR, nasal blockage is a com-
mon problem, substantially impacting the quality of life 
of the patients [19, 20]. All our patients complained of 
persistent NO. Therefore, in the present study, we used 
NIPF as an objective evaluation of NO. NIPF has been 
found to be an optimal variable to assess airflow for com-
parison over time, between subjects and in clinical trials 
[21]. As for NIPF, significant improvement (p < 0.001) 
was noted after 4 weeks of PRDNS administration, indi-
cating a positive and objective effect on NO (Table  1; 
Fig. 2). No correlation between ARCT and NIPF was ob-
served either before or after 30 days of PRDNS adminis-
tration (data not shown). This is in line with previous 
studies looking at the correlation between the sensation 
of NO and the objective measure of nasal flow [22, 23].
Interestingly, the improvement in ARCT and NIPF ob-
served after 30 days of PRDNS administration occurred in 
patients who remained uncontrolled despite PAR treat-
ments over at least 1 year, with antihistamine alone or in 
combination with intranasal steroids – and for some of 
them, decongestants as needed. The significant improve-
ment of these 2 outcomes following PRDNS administra-
tion may be related to the EOs contained in the nasal 
spray. Indeed, several components of EOs have demon-
strated anti-inflammatory and anti-allergic effects. For 
example, 1.8 cineole – which is abundant in ravintsara, 
eucalyptus radiata, and niaouli, 3 EOs contained in 
PRDNS – decreases the production of inflammatory cyto-
kines such as IL-1β, TNF-α, IL-4, and IL-5, which play an 
important role in the inflammatory allergic response [24, 
25]. The effectiveness of inhalation of 1.8-cineol-rich EOs 
on NO in patients with PAR has also been recently dem-
onstrated in a randomized placebo controlled trial [17].
In addition to the 4 EOs (ravintsara, geranium, euca-
lyptus radiata, niaouli), hypertonic saline (13%) may also 
have played a role in the improvement of ARCT and 
NIPF observed at D30. Indeed, saline irrigation with iso-
tonic or hypertonic solutions is commonly used in vari-
ous types of rhinitis, allergic or not, particularly for relief 
of NO. However, a recent systematic review of published 
randomized control trials [26] concluded that it was un-
certain that saline, in addition to pharmacological treat-
ment (antihistamines or intranasal steroids), improved 
symptoms or quality of life after 4 weeks to 3 months of 
administration compared with pharmacological treat-
ments alone. As a large number of patients included in the 
present study had persistent rhinitis symptoms, particu-
larly NO, while receiving antihistamine and nasal ste-
roids, the role of saline alone in the improvement of 
ARCT and NIPF at D30 seems unlikely. Possible limita-
tions of the study include the small sample size, the ab-
sence of a placebo control group (with hypertonic saline 
alone), and the short time of treatment and follow-up.
According to our hypothesis based on 20% improve-
ment of ARCT, the primary outcome after 30 days of 
PRDNS administration, 60 patients were required. Due to 
enrollment issues, we decided to stop enrollment after 43 
patients had been included. Despite this lower number of 
patients included, our data showed a marked significant 
improvement in ARCT and PRDNS. This suggests that 
the effect of PRDNS on these 2 outcomes, assumed to be 
20% improvement from D0 to D30 to calculate the num-
ber of patients to treat, may have been underestimated. It 
is well known that the placebo effect has a potential influ-
ence on AR studies [27]. However, our aim was to evaluate 
the effect of the PRDNS spray longitudinally, and each 
patient was his own control. Furthermore, 40 patients 
among the 43 included were already treated for their AR 
and remained uncontrolled with bothersome NO. The lat-
ter was assessed using NIPF, which is an objective mea-
surement of nasal patency [21]. Although we cannot ex-
clude a possible placebo effect, the latter would not fully 
explain the improvement in NIPF observed after 30 days 
of PRDNS administration. Another possible limitation of 
the study is that seasonal changes might have contributed 
to symptoms improvement, especially in polysensitized 
patients. One last limitation is the short duration of treat-
ment (30 days). We cannot assume that the benefit ob-
served after 30 days would be maintained with a longer 
treatment. Nevertheless, the present work is a pilot study 
and further longer studies in patients with PAR are need-
ed to assess the persistent benefit of the nasal spray.
Only 3 patients among the 43 had no treatment at in-
clusion in the study. Although these 3 patients exhibited 
a marked improvement in ARCT and NIPF after 30 days 
of PRDNS administration, a study in PAR naive patients 
would be necessary to assess the effectiveness of PRDNS 
compared to antihistamines and nasal corticosteroids. Fi-
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nally, no moderate-to-severe side effects were noted, con-
firming the safety of PRDNS.
PAR is a significant health problem, which can signif-
icantly affect patient’s quality of life. The current study 
showed the excellent tolerance of a nasal spray of hyper-
tonic saline and EOs and found an association between 
its use and the reduction of symptoms in patients with 
PAR. Patient adherence and patient preferences related 
to medication selection may lead to better treatment out-
comes. The PRDNS nasal spray is a natural and well-tol-
erated new option in the management of PAR. Further 
studies are needed to better determine its place in the 
PAR armamentarium.
Statement of Ethics
The study was approved by a local French Ethics Committee 
(Registration No. ID-RCB: 2018-A00836-49) and registered on 
ClinicalTrials.gov (No. NCT03963076). All participants signed an 
informed consent document, including consent for publication.
Conflict of Interest Statement
The authors have no conflicts of interest to declare. The fund-
ing source had no role in the design, conduct, or analysis of the 
study or the decision to submit the manuscript for publication.
Funding Sources
This study was supported by the company “Puressentiel.”
Author Contributions
Conception and design: D.C., G.T., and P.D. Acquisition of 
data: D.C., C.N., R.L., and O.M. Analysis and interpretation of 
data: D.C., G.T., and P.D. Drafting or revising the manuscript for 
important intellectual content: D.C., C.N., R.L., O.M., G.T., and 
P.D. Final approval of the version to be published: D.C., C.N., R.L., 
O.M., G.T., and P.D. Agreement to be accountable for all aspects 
of the work: D.C., C.N., R.L., O.M., G.T., and P.D.
References
 1 Small P, Keith PK, Kim H. Allergic rhinitis. 
Allergy Asthma Clin Immunol. 2018 Sep; 
14(Suppl 2): 51.
 2 Dykewicz MS, Hamilos DL. Rhinitis and si-
nusitis. J Allergy Clin Immunol. 2010 Feb; 
125(2 Suppl 2): S103–15.
 3 Bousquet J, Neukirch F, Bousquet PJ, Gehano 
P, Klossek JM, Le Gal M, et al. Severity and 
impairment of allergic rhinitis in patients 
consulting in primary care. J Allergy Clin Im-
munol. 2006 Jan; 117(1): 158–62.
 4 Bousquet J, Khaltaev N, Cruz AA, Denburg J, 
Fokkens WJ, Togias A, et al. Allergic rhinitis 
and its impact on asthma (ARIA)2008 update 
(in collaboration with the world health Orga-
nization, GA(2)LEN and AllerGen). Allergy. 
2008 Apr; 63(Suppl 86): 8–160.
 5 Demoly P, Allaert FA, Lecasble M. ERASM, a 
pharmacoepidemiologic survey on manage-
ment of intermittent allergic rhinitis in every 
day general medical practice in France. Al-
lergy. 2002 Jun; 57(6): 546–54.
 6 Benninger M, Farrar JR, Blaiss M, Chipps B, 
Ferguson B, Krouse J, et al. Evaluating ap-
proved medications to treat allergic rhinitis in 
the United States: an evidence-based review 
of efficacy for nasal symptoms by class. Ann 
Allergy Asthma Immunol. 2010 Jan; 104(1): 
13–29.
 7 Yanez A, Rodrigo GI. Intranasal corticoste-
roides versus topical H1 receptor antagonist 
for the treatment of allergic rhinitis: a system-
atic review with meta-analysis. Ann Allergy 
Asthma Immunol. 2002 Nov; 89(5): 479–84.
 8 Pullerits T, Praks L, Ristioja V, Lötvall J. Com-
parison of a nasal glucocorticoid, antileukot-
riene, and a combination of antileukotriene 
and antihistamine in the treatment of season-
al allergic rhinitis. J Allergy Clin Immunol. 
2002 Jun; 109(6): 949–55.
 9 May JR, Dolen WK. Evaluation of intranasal 
corticosteroid sensory attributes and patient 
preference for fluticasone furoate for the 
treatment of allergic rhinitis. Clin Ther. 2019 
Aug; 41(8): 1589–96.
10 Weiner JM, Abramson MJ, Puy RM. Intrana-
sal corticosteroids versus oral H1 receptor an-
tagonists in allergic rhinitis: systematic review 
of randomised controlled trials. BMJ. 1998 
Dec; 317(7173): 1624–9.
11 El W, Harris WC, Babcock CM, Alexander 
BH, Riley CA, McCoul ED. Epistaxis risk as-
sociated with intranasal corticosteroids 
sprays: a systemic review and meta-analysis. 
Otolaryngol Head Neck Surg. 2019 Jul; 161(1): 
18–27.
12 Qiu J, Grine K. Complementary and alterna-
tive treatment for allergic conditions. Prim 
Care. 2016 Sep; 43(3): 519–26.
13 Kem J, Bielory L. Complementary and alter-
native therapy (CAM) in the treatment of al-
lergic rhinitis. Curr Allergy Asthma Rep. 2014 
Dec; 14(12): 479.
14 Surda P, Fokkens WJ. Novel, alternative, and 
controversial therapies of rhinitis. Immunol 
Allergy Clin North Am. 2016 May; 36(2): 401–
23.
15 De Cassia da Silveira e Sà R, Andrade LN, de 
Sousa DP. A review on anti-inflammatory ac-
tivity of monoterpenes. Molecules. 2013 Jan; 
18(1): 1227–54.
16 Ueno-Lio T, Shibakura M, Yokota K, Aoe M, 
Hyoda T, Shinoata R, et al. Lavender essential 
oil inhalation suppresses allergic inflamma-
tion and mucus cell hyperplasia in a murine 
model of asthma. Life Sci. 2014 Jul; 108(2): 
109–15.
17 Choi Y, Park K. Effect of inhalation of aroma-
therapy oil with perennial allergic rhinitis: a 
randomized controlled trial. Evid Based 
Complement Alternat Med. 2016 Mar; 2016: 
2103616.
18 Demoly P, Jankowski R, Chassany O, Bessah 
Y, Allaert FA. Validation of a self-question-
naire for assessing the control of allergic rhi-
nitis. Clin Exp Allergy. 2011 Jun; 41(6): 860–
8.
19 Ottaviano G, Fokkens WJ. Measurements of 
nasal airflow and patency: a critical review 
with emphasis on the use of peak nasal inspi-
ratory flow in daily practice. Allergy. 2016 
Feb; 71(2): 162–74.
20 Ryden O, Andersson B, Andersson M. Dis-
ease perception and social behavior in persis-
tent rhinitis: a comparison between patients 
allergic and nonallergic rhinitis. Allergy. 2004 
Apr; 59(4): 461–4.
21 Braniuk JN. Subjective nasal fullness and ob-
jective congestion. Proc Am Thorac Soc. 2011 
Mar; 8(1): 62–9.
Allergic Rhinitis and Essential Oils 189Int Arch Allergy Immunol 2021;182:182–189
DOI: 10.1159/000510592
22 Panagou P, Loukides S, Tsipra S, Syrigou K, 
Anastasakis C, Kalogeropoulos N. Evaluation 
of nasal patency: comparison of patients and 
clinician assessments with rhinomanometry. 
Acta Otolaryngol. 1998 Nov; 118(6): 847–51.
23 Morrissey MS, Alun-Jones T, Hill J. The rela-
tionship of peak inspiratory airflow to subjec-
tive airflow in the nose. Clin Otolaryngol Al-
lied Sci. 1990 Oct; 15(5): 447–51.
24 Juergens UR, Dethlefsen U, Steinkamp G, 
Gillissen R, Repges R, Vetter H. Anti-inflam-
matory activity of 1.8 cineol in bronchial asth-
ma: a double-blind placebo controlled trial. 
Respir Med. 2003 Mar; 97(3): 250–6.
25 Bastos PD, Gomes AS, Lima FJB, Brito TS, 
Soares PM, Pinho JP, et al. Inhaled 1.8 cineole 
reduces inflammatory parameters in airways 
of ovalbumin-challenged guinea pigs. Basic 
Clin Pharmacol Toxicol. 2011 Jan; 108(1): 34–
9.
26 Head K, Snidvongs K, Glew S, Scadding G, 
Schilder AG, Philpott C, et al. Saline irrigation 
for allergic rhinitis. Cochrane Database Syst 
Rev. 2018 Jun; 6(6): CD012597.
27 Meltzer EO, Weiler JM, Widlitz MD. Com-
parative outdoor study of the efficacy, onset 
and duration of action, and safety of cetiri-
zine, loratadine, and placebo for seasonal al-
lergic rhinitis. J Allergy Clin Immunol. 1996 
Feb; 97(2): 617–26.
